Advertisement

Tumor Biology

, Volume 37, Issue 2, pp 2629–2634 | Cite as

TRIM37 promoted the growth and migration of the pancreatic cancer cells

  • Jianxin Jiang
  • She Tian
  • Chao Yu
  • Meiyuan Chen
  • Chengyi Sun
Original Article

Abstract

Increasing evidence indicated that tripartite motif containing 37 (TRIM37) was involved in the tumorigenesis of several cancer types. However, its expression pattern and biological functions in pancreatic ductal adenocarcinoma (PDAC) remained unknown. In this study, real-time PCR, Western blot and immunohistochemistry was performed to examine the expression of TRIM37 in the pancreatic cancerous tissues. Colony formation assay and cell migration assay were performed to study the functions of TRIM37 in pancreatic cancer cells. Dual-luciferase assay was performed to study the regulation of TRIM37 on beta-catenin/TCF signaling. It was found that the expression level of TRIM37 was significantly higher in pancreatic cancerous tissues compared with the adjacent normal tissues. Function analysis indicated that overexpression of TRIM37 promoted the growth and migration of the pancreatic cancer cells, while knocking down the expression of TRIM37 inhibited the growth and migration of the pancreatic cancer cells. The molecular mechanism study suggested that TRIM37 interacted with beta-catenin and activated the transcriptional activity of beta-catenin/TCF complex as well as the expression of its downstream target genes. Taken together, our study showed the oncogenic roles of TRIM37 in pancreatic cancer, and TRIM37 might be a promising target for pancreatic cancer treatment.

Keywords

Pancreatic cancer TRIM37 Cell growth and migration Beta-catenin/TCF 

Notes

Conflicts of interest

None

Supplementary material

13277_2015_4078_Fig5_ESM.jpg (837 kb)
Figure S1

The expression of TRIM37 did not affect the expression of Wnt 3a. BXPC3 and Suit2 cells were overexpressed TRIM37 or knocked down the expression of TRIM37, and the mRNA level of Wnt3a was examined using qPCR. (JPEG 837 kb)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Liang C, Wang Z, Li YY, Yu BH, Zhang F, Li HY. Mir-33a suppresses the nuclear translocation of beta-catenin to enhance gemcitabine sensitivity in human pancreatic cancer cells. Tumour Biol. (ahead of print). 2015.Google Scholar
  3. 3.
    Jiang S, Zhu L, Tang H, et al. Ape1 regulates wnt/beta-catenin signaling through its redox functional domain in pancreatic cancer cells. Int J Oncol. (ahead of print). 2015.Google Scholar
  4. 4.
    Chen X, Liu X, Lang H, Zhang S, Luo Y, Zhang J. S100 calcium-binding protein a6 promotes epithelial-mesenchymal transition through beta-catenin in pancreatic cancer cell line. PLoS One. 2015;10:e0121319.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Kumaran S, Samantha KS, Halagowder D. Does beta-catenin cross-regulate NFkappaB signalling in pancreatic cancer and chronic pancreatitis? Pathobiology. 2015;82:28–35.CrossRefPubMedGoogle Scholar
  6. 6.
    Xu W, Wang Z, Zhang W, et al. Mutated k-ras activates cdk8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the wnt/beta-catenin signaling pathway. Cancer Lett. 2015;356:613–27.CrossRefPubMedGoogle Scholar
  7. 7.
    Macdonald BT, Semenov MV, He X. Snapshot: Wnt/beta-catenin signaling. Cell. 2007;131:1204.CrossRefPubMedGoogle Scholar
  8. 8.
    Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149:1192–205.CrossRefPubMedGoogle Scholar
  9. 9.
    Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469–80.CrossRefPubMedGoogle Scholar
  10. 10.
    Kallijarvi J, Lahtinen U, Hamalainen R, Lipsanen-Nyman M, Palvimo JJ, Lehesjoki AE. Trim37 defective in mulibrey nanism is a novel ring finger ubiquitin e3 ligase. Exp Cell Res. 2005;308:146–55.CrossRefPubMedGoogle Scholar
  11. 11.
    Bhatnagar S, Gazin C, Chamberlain L, et al. Trim37 is a new histone h2a ubiquitin ligase and breast cancer oncoprotein. Nature. 2015;516:116–20.Google Scholar
  12. 12.
    Dimova I, Orsetti B, Negre V, et al. Genomic markers for ovarian cancer at chromosomes 1, 8 and 17 revealed by array cgh analysis. Tumori. 2009;95:357–66.PubMedGoogle Scholar
  13. 13.
    Karlberg S, Lipsanen-Nyman M, Lassus H, Kallijarvi J, Lehesjoki AE, Butzow R. Gynecological tumors in mulibrey nanism and role for ring finger protein trim37 in the pathogenesis of ovarian fibrothecomas. Mod Pathol. 2009;22:570–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Brodtkorb M, Lingjaerde OC, Huse K, Troen G, et al. Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. Blood. 2014;123:1051–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Balestra FR, Strnad P, Fluckiger I, Gonczy P. Discovering regulators of centriole biogenesis through siRNA-based functional genomics in human cells. Dev Cell. 2013;25:555–71.CrossRefPubMedGoogle Scholar
  16. 16.
    Tuna M, Smid M, Martens JW, Foekens JA. Prognostic value of acquired uniparental disomy (aupd) in primary breast cancer. Breast Cancer Res Treat. 2012;132:189–96.CrossRefPubMedGoogle Scholar
  17. 17.
    Hamalainen RH, Mowat D, Gabbett MT, O’Brien TA, Kallijarvi J, Lehesjoki AE. Wilms’ tumor and novel trim37 mutations in an Australian patient with mulibrey nanism. Clin Genet. 2006;70:473–9.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Jianxin Jiang
    • 1
  • She Tian
    • 1
  • Chao Yu
    • 1
  • Meiyuan Chen
    • 1
  • Chengyi Sun
    • 1
  1. 1.Department of Biliary-Hepatic SurgeryAffiliated Hospital of Guiyang Medical CollegeGuiyangChina

Personalised recommendations